113 related articles for article (PubMed ID: 8674057)
41. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
[TBL] [Abstract][Full Text] [Related]
42. NTP Toxicology and Carcinogenesis Studies of Triamterene (CAS No. 396-01-0) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Dec; 420():1-367. PubMed ID: 12616291
[TBL] [Abstract][Full Text] [Related]
43. Overview of interleukin-2 inhalation therapy.
Huland E; Heinzer H; Huland H; Yung R
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
[TBL] [Abstract][Full Text] [Related]
44. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
45. NTP Toxicology and Carcinogenesis Studies of Promethazine Hydrochloride (CAS No. 58-33-3) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Dec; 425():1-272. PubMed ID: 12616286
[TBL] [Abstract][Full Text] [Related]
46. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
47. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
48. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
[TBL] [Abstract][Full Text] [Related]
49. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
50. Dermatologic changes associated with adoptive immunotherapy of cancer.
Gaspari AA
Semin Dermatol; 1991 Sep; 10(3):178-87. PubMed ID: 1931566
[TBL] [Abstract][Full Text] [Related]
51. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts.
Geoerger B; Tang CB; Cesano A; Visonneau S; Marwaha S; Judy KD; Sutton LN; Santoli D; Phillips PC
Neuro Oncol; 2000 Apr; 2(2):103-13. PubMed ID: 11303619
[TBL] [Abstract][Full Text] [Related]
52. Phase I clinical trial of MAF containing preparation of RPMI-1788 B-cell human lymphoblastoid lymphokine in advanced cancer patients.
Reynolds RD; Khojasteh A; Papermaster BW; McEntire JE
Lymphokine Res; 1986; 5 Suppl 1():S165-70. PubMed ID: 3537547
[TBL] [Abstract][Full Text] [Related]
53. Tumoricidal responses in spontaneous canine neoplasms after extracorporeal perfusion over immobilized protein A.
Terman DS
Fed Proc; 1981 Jan; 40(1):45-9. PubMed ID: 7450063
[TBL] [Abstract][Full Text] [Related]
54. Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice.
Cesano A; Visonneau S; Tran T; Santoli D
Int J Oncol; 1999 Feb; 14(2):245-51. PubMed ID: 9917498
[TBL] [Abstract][Full Text] [Related]
55. Prospects of T-cell immunotherapy for cancer by peptide vaccination.
Melief CJ
Semin Hematol; 1993 Jul; 30(3 Suppl 3):32-3. PubMed ID: 8235703
[No Abstract] [Full Text] [Related]
56. Radiotherapy-induced myelosuppression in dogs: 103 cases (2002-2006).
Clermont T; Leblanc AK; Adams WH; Leblanc CJ; Bartges JW
Vet Comp Oncol; 2012 Mar; 10(1):24-32. PubMed ID: 22236056
[TBL] [Abstract][Full Text] [Related]
57. Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy.
Cejalvo T; Perisé-Barrios AJ; Del Portillo I; Laborda E; Rodriguez-Milla MA; Cubillo I; Vázquez F; Sardón D; Ramirez M; Alemany R; Del Castillo N; García-Castro J
Cancer Res; 2018 Sep; 78(17):4891-4901. PubMed ID: 29991502
[TBL] [Abstract][Full Text] [Related]
58. Quality of life-improving effect of autologous ex vivo expanded cytotoxic and opioid-producing lymphocytes for dogs with cancers.
Mitani K; Ito Y; Takene Y; Hatoya S; Sugiura K; Inaba T
Vet Immunol Immunopathol; 2021 Aug; 238():110292. PubMed ID: 34246811
[TBL] [Abstract][Full Text] [Related]
59. Adoptive cell transfer: new perspective treatment in veterinary oncology.
Bujak JK; Pingwara R; Nelson MH; Majchrzak K
Acta Vet Scand; 2018 Oct; 60(1):60. PubMed ID: 30305130
[TBL] [Abstract][Full Text] [Related]
60. Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors.
Thamm DH; Kurzman ID; Macewen EG; Feinmehl R; Towell TL; Longhofer SL; Johnson CM; Geoly FJ; Stinchcomb DT
Cancer Immunol Immunother; 2003 Aug; 52(8):473-80. PubMed ID: 12768328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
